Analyst Reco. Nevro Corp.

Equities

NVRO

US64157F1030

Real-time Estimate Cboe BZX Other stock markets 02:35:32 2024-06-06 pm EDT			5-day change	1st Jan Change
9.275 ^USD	+0.05%		+1.04%	-56.95%

May. 22	Citigroup Downgrades Nevro to Sell From Neutral, Adjusts Price Target to $9 From $13.50	MT
May. 14	Transcript : Nevro Corp. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Downgrades Nevro to Sell From Neutral, Adjusts Price Target to $9 From $13.50	May. 22	MT
Truist Securities Lowers Nevro's Price Target to $11 From $14, Hold Rating Maintained	May. 08	MT
Piper Sandler Adjusts Nevro's Price Target to $12 From $15, Maintains Underweight Rating	May. 08	MT
Wells Fargo Trims Nevro Price Target to $13 From $14, Maintains Equal Weight Rating	May. 08	MT
RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating	Apr. 15	MT
Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating	Apr. 11	MT
Citigroup Cuts Price Target on Nevro to $16 From $18, Maintains Neutral Rating	Apr. 03	MT
Wells Fargo Adjusts Price Target on Nevro to $17 From $20, Maintains Equal-Weight Rating	Feb. 22	MT
Baird Cuts Price Target on Nevro to $19 From $23, Maintains Neutral Rating	Feb. 22	MT
Oppenheimer Downgrades Nevro to Perform From Outperform, Removes $35 Price Target	Feb. 22	MT
RBC Lowers Price Target on Nevro to $18 From $20, Keeps Sector Perform Rating	Feb. 22	MT
RBC Downgrades Nevro to Sector Perform From Outperform, Cuts Price Target to $20 From $23	Jan. 12	MT
Truist Securities Adjusts Price Target on Nevro to $23 From $22, Maintains Hold Rating	Dec. 22	MT
Canaccord Genuity Downgrades Nevro to Hold From Buy, $23 Price Target	Dec. 21	MT
Truist Securities Adjusts Price Target on Nevro to $17 From $18.50, Keeps Hold Rating	Nov. 03	MT
Morgan Stanley Cuts Price Target on Nevro to $18 From $23, Calls Q4 Guidance 'Wary,' Keeps Equalweight Rating	Nov. 02	MT
BofA Cuts Price Target on Nevro to $17 From $28, Keeps Underperform Rating	23-10-18	MT
Citigroup Adjusts Price Target on Nevro to $21 From $24, Maintains Neutral Rating	23-08-21	MT
Truist Securities Adjusts Nevro's Price Target to $25 From $27, Keeps Hold Rating	23-08-03	MT
Morgan Stanley Adjusts Price Target on Nevro to $23 From $29, Maintains Equalweight Rating	23-08-02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Nevro Corp.

Equities

NVRO

US64157F1030

Analyst Reco.

Filters